Abstract:In our previous study, we reported a series of N-(9,10-anthraquinone-2-carbonyl) amino acid derivatives as novel inhibitors of xanthine oxidase (XO). Recognizing the suboptimal drug-like properties associated with the anthraquinone moiety, we embarked on a nonanthraquinone medicinal chemistry exploration in the current investigation. Through systematic structure-activity relationship (SAR) studies, we identified a series of 4-(isopentyloxy)-3-nitrobenzamide derivatives exhibiting excellent in vitro potency against XO. The optimized compound, 4-isopentyloxy-N-(1H-pyrazol-3-yl)-3-nitrobenzamide (6k), demonstrated exceptional in vitro potency with an IC50 value of 0.13 μM. Compound 6k showed favorable drug-like characteristics with ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of 0.41 and 3.73, respectively. In comparison to the initial compound 1d, 6k exhibited a substantial 24-fold improvement in IC50, along with a 1.6-fold enhancement in LE and a 3.7-fold increase in LLE. Molecular modeling studies provided insights into the strong interactions of 6k with critical amino acid residues within the active site. Furthermore, in vivo hypouricemic investigations convincingly demonstrated that 6k significantly reduced serum uric acid levels in rats. The MTT results revealed that compound 6k is nontoxic to healthy cells. The gastric and intestinal stability assay demonstrated that compound 6k exhibits good stability in the gastric and intestinal environments. In conclusion, compound 6k emerges as a promising lead compound, showcasing both exceptional in vitro potency and favorable drug-like characteristics, thereby warranting further exploration.

Design and Synthesis of Novel Arctigenin Analogues for the Amelioration of Metabolic Disorders.

Arctigenin: Pharmacology, Total Synthesis, and Progress in Structure Modification

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

Synthesis of 6-Hydroxyaurone Analogues and Evaluation of Their Α-Glucosidase Inhibitory and Glucose Consumption-Promoting Activity: Development of Highly Active 5,6-Disubstituted Derivatives

Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl)propanamides as glucokinase activators.

Serial five-membered lactone ring ions in the treatment of Alzheimer's diseases-comprehensive profiling of arctigenin metabolites and network analysis

Design and synthesis of epigallocatechin (EGC) analogs selective to inhibit α-amylase over α-glucosidases via the incorporation of caffeine acid and its derivatives

Design, Synthesis and Biological Evaluation of GY3-based Derivatives for Anti-Type 2 Diabetes Activity.

Structure-Based Design of Marine-derived Meridianin C Derivatives As Glycogen Synthase Kinase 3β Inhibitors with Improved Oral Bioavailability: from Aminopyrimidyl-Indoles to the Sulfonyl Analogues

Design, synthesis and inhibition evaluation of novel chalcone amide α-glucosidase inhibitors

Design, synthesis and structure-activity relationship of N-phenyl aromatic amide derivatives as novel xanthine oxidase inhibitors

Synthesis & Alpha-Glucosidase Inhibitory & Glucose Consumption-Promoting Activities O Flavonoid-Coumarin Hybrids

Design, synthesis and structural-activity relationship studies of phanginin A derivatives for regulating SIK1-cAMP/CREB signaling to suppress hepatic gluconeogenesis

Synthesis and biological evaluation of novel ursolic acid analogues as potential α-glucosidase inhibitors

Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold

Semisynthesis, Biological Activities, and Mechanism Studies of Mannich Base Analogues of Magnolol/honokiol As Potential Α-Glucosidase Inhibitors.

Design, Synthesis and Biological Evaluation of 4,7,12,12A-Tetrahydro-5h-thieno[3',2':3,4]Pyrido[1,2-b]isoquinolines As Novel Adenosine 5'-Monophosphate-activated Protein Kinase (AMPK) Indirect Activators for the Treatment of Type 2 Diabetes.

The Discovery of Novel α2a Adrenergic Receptor Agonists Only Coupling to Gαi/O Proteins by Virtual Screening

Apigenin analogs as α-glucosidase inhibitors with antidiabetic activity

Design, synthesis and structure-activity relationship of novel 2-pyrimidinylindole derivatives as orally available anti-obesity agents

Discovery of 4-(isopentyloxy)-3-nitrobenzamide derivatives as xanthine oxidase inhibitors through a non-anthraquinone exploration